Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 10;8(17):4647-4650.
doi: 10.1182/bloodadvances.2024013280.

Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia

Andrew Palmer  1 , Garth Rauscher  2 , Ivy Abraham  3 , Madelyn Burkart  4 , Ami Dave  5 , Nepheli Raptis  6 , Ahmed Aleem  7 , Vedavyas Gannamani  8 , Amani Erra  8 , Sarah Monick  9 , Carlos Galvez  10 , Syed Shah  11 , Hamed Rahmani Youshanlouei  11 , Melissa L Larson  5 , Maryam Zia  8 , Stephanie B Tsai  7 , Jessica K Altman  12 , Wendy Stock  11 , Irum Khan  12 , Anand A Patel  11
Affiliations

Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia

Andrew Palmer et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.B.T. reports honoraria from Jazz and Sanofi, and advisory board fees from Bristol Myers Squibb. J.K.A. reports consultancy fees from AbbVie, Aptitude Health, Astellas Pharma, BioSight, bluebird bio, Curio, Daiichi Sankyo, Dark Blue Therapeutics, Gilead, Kura Oncology, Kymera, Stemline Therapeutics, Treadwell Therapeutics, Rigel, and Syros, and research funding from AbbVie, Agios, ALX Oncology, Amgen, Amphivena, Aprea AB, Aptose Biosciences, Astellas Pharma, BioSight, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cyclacel Pharmaceuticals, Fujifilm, ImmunoGen, Kartos Therapeutics, Kura Oncology, Loxo, and Pfizer. W.S. reports adviser fees from Kura, Servier, Newave, and Asofarma. A.A.P. reports honoraria from AbbVie, Bristol Myers Squibb, and Sobi, and research funding from Pfizer, Kronos Bio, and Sumitomo. The remaining authors declare no competing financial interests.

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. - PubMed
    1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. - PubMed
    1. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17(9):513–527. - PMC - PubMed
    1. Master S, Munker R, Shi Z, Mills G, Shi R. Insurance status and other non-biological factors predict outcomes in acute myelogenous leukemia: analysis of data from the national cancer database. Anticancer Res. 2016;36(9):4915–4921. - PubMed
    1. Rebechi M, Kohlschmidt J, Mrózek K, et al. Association of social deprivation with survival in younger adult patients with AML: an alliance study. Blood Adv. 2023;7(15):4019–4023. - PMC - PubMed